tetano
Editor, Senior Moderator
J Virol
. 2022 Aug 29;e0123822.
doi: 10.1128/jvi.01238-22. Online ahead of print.
Specific Monoclonal Antibodies Targeting Unique HA Epitopes Block H7N9 Influenza A Viral Replication
Wentao Shen[SUP] 1 [/SUP], Qian Wang[SUP] 1 [/SUP], Zhengxiang Wang[SUP] 1 [/SUP], Minxuan Liu[SUP] 1 [/SUP], Yingying Du[SUP] 1 [/SUP], Lvfeng Yuan[SUP] 1 [/SUP], Lu Han[SUP] 1 [/SUP], Krzysztof Smietanka[SUP] 2 [/SUP], Hualan Chen[SUP] 3 [/SUP], Shuai Xu[SUP] 1 [/SUP], Qiyun Zhu[SUP] 1 [/SUP]
Affiliations
Abstract
The H7N9 subtype influenza A viruses pose a serious threat to public health, and there is still a lack of vaccines or drugs for humans against H7N9 influenza viruses. In this study, we screened two monoclonal antibodies (MAbs), 4H1E8 and 7H9A6, that specifically recognize the hemagglutinin (HA) protein of H7N9 influenza virus and display highly neutralizing activity against H7N9 virus. The epitopes recognized by two MAbs are nearly all conserved within all known H7 subtypes. Characteristic identification showed that two MAbs have high avidity for the HA protein but no hemagglutinin inhibition activity or antibody-dependent cellular cytotoxicity. Mechanistically, the 4H1E8 and 7H9A6 antibodies inhibit the pH-dependent conformational change of HA and block the HA-mediated membrane fusion. More importantly, 4H1E8 and 7H9A6 exhibit promising prophylactic and therapeutic effects against lethal challenge with H7N9 virus. Moreover, 4H1E8- and 7H9A6-treated mice displayed inhibition of pulmonary viral replication and reduced lung lesions after viral challenge. Together, these findings indicate that antibodies 4H1E8 and 7H9A6 recognize unique epitopes in the HA protein and possess the neutralizing activity and protective efficacy against the H7N9 influenza A viruses. IMPORTANCE In 2013, H7N9 influenza viruses appeared in China and other countries resulting in more than 1,500 individual infections or death. There are still limited studies on vaccines or drugs for humans against H7N9 influenza viruses. Alternative approaches against H7N9 virus infection need to be developed. Here, we identified two monoclonal antibodies (4H1E8 and 7H9A6) that possess neutralizing activity by blocking the pH-dependent HA-mediated membrane fusion. Additionally, the two monoclonal antibodies protect mice against the H7N9 virus challenge prophylactically or therapeutically. Therefore, our study demonstrates that 4H1E8 and 7H9A6 could be used for the prevention and treatment of the H7N9 influenza virus, and the conserved epitopes we identified may contribute to the development of a broad H7N9 vaccine and provide insights into unique antiviral approaches.
Keywords: H7N9 influenza virus; hemagglutinin; monoclonal antibody; prophylaxis; therapy.
. 2022 Aug 29;e0123822.
doi: 10.1128/jvi.01238-22. Online ahead of print.
Specific Monoclonal Antibodies Targeting Unique HA Epitopes Block H7N9 Influenza A Viral Replication
Wentao Shen[SUP] 1 [/SUP], Qian Wang[SUP] 1 [/SUP], Zhengxiang Wang[SUP] 1 [/SUP], Minxuan Liu[SUP] 1 [/SUP], Yingying Du[SUP] 1 [/SUP], Lvfeng Yuan[SUP] 1 [/SUP], Lu Han[SUP] 1 [/SUP], Krzysztof Smietanka[SUP] 2 [/SUP], Hualan Chen[SUP] 3 [/SUP], Shuai Xu[SUP] 1 [/SUP], Qiyun Zhu[SUP] 1 [/SUP]
Affiliations
- PMID: 36037479
- DOI: 10.1128/jvi.01238-22
Abstract
The H7N9 subtype influenza A viruses pose a serious threat to public health, and there is still a lack of vaccines or drugs for humans against H7N9 influenza viruses. In this study, we screened two monoclonal antibodies (MAbs), 4H1E8 and 7H9A6, that specifically recognize the hemagglutinin (HA) protein of H7N9 influenza virus and display highly neutralizing activity against H7N9 virus. The epitopes recognized by two MAbs are nearly all conserved within all known H7 subtypes. Characteristic identification showed that two MAbs have high avidity for the HA protein but no hemagglutinin inhibition activity or antibody-dependent cellular cytotoxicity. Mechanistically, the 4H1E8 and 7H9A6 antibodies inhibit the pH-dependent conformational change of HA and block the HA-mediated membrane fusion. More importantly, 4H1E8 and 7H9A6 exhibit promising prophylactic and therapeutic effects against lethal challenge with H7N9 virus. Moreover, 4H1E8- and 7H9A6-treated mice displayed inhibition of pulmonary viral replication and reduced lung lesions after viral challenge. Together, these findings indicate that antibodies 4H1E8 and 7H9A6 recognize unique epitopes in the HA protein and possess the neutralizing activity and protective efficacy against the H7N9 influenza A viruses. IMPORTANCE In 2013, H7N9 influenza viruses appeared in China and other countries resulting in more than 1,500 individual infections or death. There are still limited studies on vaccines or drugs for humans against H7N9 influenza viruses. Alternative approaches against H7N9 virus infection need to be developed. Here, we identified two monoclonal antibodies (4H1E8 and 7H9A6) that possess neutralizing activity by blocking the pH-dependent HA-mediated membrane fusion. Additionally, the two monoclonal antibodies protect mice against the H7N9 virus challenge prophylactically or therapeutically. Therefore, our study demonstrates that 4H1E8 and 7H9A6 could be used for the prevention and treatment of the H7N9 influenza virus, and the conserved epitopes we identified may contribute to the development of a broad H7N9 vaccine and provide insights into unique antiviral approaches.
Keywords: H7N9 influenza virus; hemagglutinin; monoclonal antibody; prophylaxis; therapy.